Gilead Sciences (NASDAQ:GILD) Sees Positive Outlook from Morgan Stanley with a New Price Target

Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company known for its innovative treatments in areas such as HIV, liver diseases, and cancer. The company has a strong presence in the pharmaceutical industry, competing with other major players like Pfizer and Merck. Gilead's stock is currently trading at $108, reflecting its dynamic market activity.

On June 18, 2025, Terence Flynn from Morgan Stanley set a price target of $135 for Gilead, suggesting a potential 25% increase from its current trading price. This optimistic outlook is supported by recent developments, such as the FDA approval of Yeztugo. As highlighted by Morgan Stanley, this approval is seen as a positive step for Gilead, potentially boosting its market position. The approval of Yeztugo is a significant milestone for Gilead, aligning with investor expectations and potentially driving future growth.

This development is expected to enhance Gilead's financial performance, contributing to the company's market capitalization of approximately $134.3 billion. The stock's recent trading range, with a low of $107.2 and a high of $111.78, reflects investor interest in the company's prospects. Gilead's stock has experienced fluctuations over the past year, with a high of $119.96 and a low of $64.86. Despite these variations, the company's strong market position and recent FDA approval provide a solid foundation for future growth. Today's trading volume of 11,816,865 shares indicates active investor engagement, further supporting the positive outlook for Gilead's stock.